Protease inhibitors for prevention of ERCP pancreatitis: can we afford the price of success?
Ziebert
J J
JJ
University of Utah, Salt Lake City, USA.
Bjorkman
D J
DJ
D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects*; D003365:Costs and Cost Analysis; D016527:Drug Costs; D016670:Gabexate / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D010195:Pancreatitis / Q000209:etiology / Q000517:prevention & control*; D010919:Placebos; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome
D010919:Placebos; D015842:Serine Proteinase Inhibitors; D016670:Gabexate